Cargando…

Barriers to medications for opioid use disorder in the court system: provider availability, provider “trustworthiness,” and cost

BACKGROUND: Medications for opioid use disorder (MOUD) significantly decrease mortality but courts rarely refer participants with opioid use disorder to MOUD providers. Previous qualitative work suggests routine court referrals to MOUD providers are more likely if court team members perceive provide...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Fatema Z., Andraka-Christou, Barbara, Clark, M.H., Totaram, Rachel, Atkins, Danielle N., del Pozo, Brandon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327334/
https://www.ncbi.nlm.nih.gov/pubmed/35895179
http://dx.doi.org/10.1186/s40352-022-00188-4
_version_ 1784757486080753664
author Ahmed, Fatema Z.
Andraka-Christou, Barbara
Clark, M.H.
Totaram, Rachel
Atkins, Danielle N.
del Pozo, Brandon
author_facet Ahmed, Fatema Z.
Andraka-Christou, Barbara
Clark, M.H.
Totaram, Rachel
Atkins, Danielle N.
del Pozo, Brandon
author_sort Ahmed, Fatema Z.
collection PubMed
description BACKGROUND: Medications for opioid use disorder (MOUD) significantly decrease mortality but courts rarely refer participants with opioid use disorder to MOUD providers. Previous qualitative work suggests routine court referrals to MOUD providers are more likely if court team members perceive providers as “trustworthy.” Court team members may also be less likely to refer participants to MOUD if they consider MOUD unaffordable, particularly in Florida, which has not expanded Medicaid. Our aims were to explore court team members’ 1) perceptions of availability of local trustworthy MOUD providers, 2) characteristics associated with perceptions of availability of local trustworthy MOUD providers, including beliefs about MOUD efficacy, and 3) perceptions of MOUD affordability. METHODS: An online survey was distributed to all criminal problem-solving court and dependency court team members in Florida in 2019 and 2020. Likert scale questions assessed respondent agreement with statements about the availability of any MOUD providers, the availability of trustworthy MOUD providers, and the affordability of MOUD for court participants. An open-ended question explored MOUD barriers. Spearman’s rho, Friedman, Kruskal Wallis, and Mann-Whitney U tests were used for analyzing quantitative data and iterative categorization for qualitative data. RESULTS: One hundred fifty-one respondents completed quantitative questions (26% response rate), and 42 completed the qualitative question. Respondents were more likely to agree that local MOUD providers are more available than trustworthy MOUD providers. Perceptions of trustworthy provider availability differed significantly by MOUD type and were associated with MOUD efficacy beliefs. Qualitative results suggest that MOUD providers offering counseling and individualized treatment are more trustworthy. CONCLUSIONS: Court team MOUD beliefs may influence their perceptions of providers, or negative experiences with providers may influence court team MOUD beliefs. Improving court team perceptions of local MOUD providers may be critical for facilitating court participant treatment access. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40352-022-00188-4.
format Online
Article
Text
id pubmed-9327334
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-93273342022-07-28 Barriers to medications for opioid use disorder in the court system: provider availability, provider “trustworthiness,” and cost Ahmed, Fatema Z. Andraka-Christou, Barbara Clark, M.H. Totaram, Rachel Atkins, Danielle N. del Pozo, Brandon Health Justice Research Article BACKGROUND: Medications for opioid use disorder (MOUD) significantly decrease mortality but courts rarely refer participants with opioid use disorder to MOUD providers. Previous qualitative work suggests routine court referrals to MOUD providers are more likely if court team members perceive providers as “trustworthy.” Court team members may also be less likely to refer participants to MOUD if they consider MOUD unaffordable, particularly in Florida, which has not expanded Medicaid. Our aims were to explore court team members’ 1) perceptions of availability of local trustworthy MOUD providers, 2) characteristics associated with perceptions of availability of local trustworthy MOUD providers, including beliefs about MOUD efficacy, and 3) perceptions of MOUD affordability. METHODS: An online survey was distributed to all criminal problem-solving court and dependency court team members in Florida in 2019 and 2020. Likert scale questions assessed respondent agreement with statements about the availability of any MOUD providers, the availability of trustworthy MOUD providers, and the affordability of MOUD for court participants. An open-ended question explored MOUD barriers. Spearman’s rho, Friedman, Kruskal Wallis, and Mann-Whitney U tests were used for analyzing quantitative data and iterative categorization for qualitative data. RESULTS: One hundred fifty-one respondents completed quantitative questions (26% response rate), and 42 completed the qualitative question. Respondents were more likely to agree that local MOUD providers are more available than trustworthy MOUD providers. Perceptions of trustworthy provider availability differed significantly by MOUD type and were associated with MOUD efficacy beliefs. Qualitative results suggest that MOUD providers offering counseling and individualized treatment are more trustworthy. CONCLUSIONS: Court team MOUD beliefs may influence their perceptions of providers, or negative experiences with providers may influence court team MOUD beliefs. Improving court team perceptions of local MOUD providers may be critical for facilitating court participant treatment access. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40352-022-00188-4. Springer Berlin Heidelberg 2022-07-27 /pmc/articles/PMC9327334/ /pubmed/35895179 http://dx.doi.org/10.1186/s40352-022-00188-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Ahmed, Fatema Z.
Andraka-Christou, Barbara
Clark, M.H.
Totaram, Rachel
Atkins, Danielle N.
del Pozo, Brandon
Barriers to medications for opioid use disorder in the court system: provider availability, provider “trustworthiness,” and cost
title Barriers to medications for opioid use disorder in the court system: provider availability, provider “trustworthiness,” and cost
title_full Barriers to medications for opioid use disorder in the court system: provider availability, provider “trustworthiness,” and cost
title_fullStr Barriers to medications for opioid use disorder in the court system: provider availability, provider “trustworthiness,” and cost
title_full_unstemmed Barriers to medications for opioid use disorder in the court system: provider availability, provider “trustworthiness,” and cost
title_short Barriers to medications for opioid use disorder in the court system: provider availability, provider “trustworthiness,” and cost
title_sort barriers to medications for opioid use disorder in the court system: provider availability, provider “trustworthiness,” and cost
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327334/
https://www.ncbi.nlm.nih.gov/pubmed/35895179
http://dx.doi.org/10.1186/s40352-022-00188-4
work_keys_str_mv AT ahmedfatemaz barrierstomedicationsforopioidusedisorderinthecourtsystemprovideravailabilityprovidertrustworthinessandcost
AT andrakachristoubarbara barrierstomedicationsforopioidusedisorderinthecourtsystemprovideravailabilityprovidertrustworthinessandcost
AT clarkmh barrierstomedicationsforopioidusedisorderinthecourtsystemprovideravailabilityprovidertrustworthinessandcost
AT totaramrachel barrierstomedicationsforopioidusedisorderinthecourtsystemprovideravailabilityprovidertrustworthinessandcost
AT atkinsdaniellen barrierstomedicationsforopioidusedisorderinthecourtsystemprovideravailabilityprovidertrustworthinessandcost
AT delpozobrandon barrierstomedicationsforopioidusedisorderinthecourtsystemprovideravailabilityprovidertrustworthinessandcost